{"entity":{"id":"nkt2152","kind":"drug","name":"NKT2152","aka":[],"tldr":"NKT2152 is an experimental pill from NiKang Therapeutics, in phase 2 trials for clear cell renal cell carcinoma.","summary":"NKT2152 is a small molecule, oral from NiKang Therapeutics. An allosteric inhibitor of HIF-2α (HIF2-alpha) that breaks up the HIF2-alpha and HIF1-beta complex. Both NiKang-sponsored studies in clear cell renal cell carcinoma (NCT05119335 and NCT05935748, the second with palbociclib and sasanlimab) are terminated; the sources read do not say whether kidney cancer development continues. It is also one of the drugs in Roche's MORPHEUS-Liver platform study in liver cancer.","status":"phase-2","asOf":"2026-11-04","links":[{"label":"NiKang science and pipeline","url":"https://www.nikangtx.com/science-and-pipeline/"},{"label":"ClinicalTrials.gov NCT04524871","url":"https://clinicaltrials.gov/study/NCT04524871"},{"label":"ClinicalTrials.gov NCT05119335","url":"https://clinicaltrials.gov/study/NCT05119335"},{"label":"ClinicalTrials.gov NCT05935748","url":"https://clinicaltrials.gov/study/NCT05935748"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["clear-cell-rcc"],"sections":[],"technologies":[],"targets":["hif2a"],"drugs":[],"companies":["nikang-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05119335","nct05935748"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"NKT2152","modality":"Small molecule, oral","mechanism":"An allosteric inhibitor of HIF-2α (HIF2-alpha) that breaks up the HIF2-alpha and HIF1-beta complex.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/nkt2152/","neighbours":{"cancer":[{"id":"clear-cell-rcc","kind":"cancer","name":"Clear cell renal cell carcinoma","route":"/cancers/clear-cell-rcc/"}],"target":[{"id":"hif2a","kind":"target","name":"HIF-2α","route":"/targets/hif2a/"}],"company":[{"id":"nikang-therapeutics","kind":"company","name":"NiKang Therapeutics","route":"/companies/nikang-therapeutics/"}],"trial":[{"id":"nct05119335","kind":"trial","name":"A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma","route":"/trials/nct05119335/"},{"id":"nct05935748","kind":"trial","name":"Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)","route":"/trials/nct05935748/"}]}}